BMLBMLKF 69 EBITDA Margin % is 30.75% as of Mar. 2026, which is 128% above its 10-year median of 13.46. GuruFocus rates BMLKF with a GF Score™ of 69/100 and a GF Value™ of $26.78. The stock has 2 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, BML ranks better than 62.25% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. BML's EBITDA for the
three
months ended in Mar. 2026 was $69.3 Mil. BML's Revenue for the
three
months ended in Mar. 2026 was $225.5 Mil. Therefore, BML's EBITDA margin for the quarter that ended in Mar. 2026 was 30.75%.
BML (OTCPK:BMLKF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
BML EBITDA Margin % Related Terms
BML EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for BML's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BMLKF vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, BML's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BML EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BML's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where BML's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BML (BMLKF) has a EBITDA Margin % of 30.75% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BML and its competitors. This is 128% above median its historical median of 13.46. Over the past decade, BML's EBITDA Margin % has ranged from 11.83 to 30.19. According to the industry distribution chart, BML ranks #77 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 37.7%.
Is BML's EBITDA Margin % too high?
BML's current EBITDA Margin % of 30.75% is 128% above median its 10-year median of 13.46. Over the past 10 years, this metric has ranged from a low of 11.83 to a high of 30.19. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. BML's value of 30.75% is 491.3% above this industry median. Based on the distribution chart, BML ranks #77 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BML has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does BML's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BML ranks #77 out of 204 companies for EBITDA Margin %. This puts BML in the upper half of its industry. The industry median EBITDA Margin % is 5.20. BML's value of 30.75% is 491.3% above this benchmark. Historically, BML's own EBITDA Margin % has ranged from 11.83 to 30.19 over the past decade. While the company's 10-year median is 13.46 vs. the industry median of 5.20, BML has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BML's current EBITDA Margin % of 30.75% is 491.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on BML and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BML's current EBITDA Margin % is 30.75%, which is 128% above median its own 10-year median of 13.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BML stock overvalued right now?
BML (BMLKF) has a current EBITDA Margin % of 30.75%. The stock's GF Value™ is $26.78, compared to a current price of $25.21 — trading 5.9% below its estimated fair value. The current EBITDA Margin % is 30.75%, which is 128% above median its 10-year median of 13.46 and 491.3% above the Medical Diagnostics & Research industry median of 5.20. BML's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For BML (BMLKF), the current EBITDA Margin % is 30.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BML (BMLKF) Overvalued in 2026?
Based on GuruFocus' analysis, BML stock appears to be undervalued.
The current stock price of $25.21 is trading 5.9% below its estimated GF Value™ of $26.78.
Key valuation signals for BMLKF:
EBITDA Margin %: 30.75% (128% above median its 10-year median of 13.46)
GF Value™: $26.78 vs. price of $25.21 (5.9% below fair value)
Industry Position: 491.3% above the Medical Diagnostics & Research median (#77 of 204)
No single metric tells the full story. See the BMLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BML Inc provides laboratory testing services in Japan through a network of regional facilities. Its core clinical testing business provides a range of general and specialty laboratory tests, as well as microbiological tests that can be used for applications like food sanitation and environmental analysis. BML often uses automated systems to process and analyze these test samples. In addition to its clinical testing business, BML also has a medical information systems business and a genome-related business. The medical information systems business provides electronic medical charts and information systems that can be used in conjunction with its laboratory tests. The genome business provides gene analysis services.
69GF Score
Get the complete analysis for BMLKF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMLKF has been successfully added to your 
